Total cash and cash equivalents were $392.1 million as of December 31, 2024. Based on current plans and related estimates of anticipated cash inflows from DEXTENZA, the Company believes that its current cash balance is sufficient to support its planned expenses, debt service obligations, and capital expenditure requirements into 2028. This cash projection does not factor in the potential impact of clinical trial activities for AXPAXLI in NPDR and DME, however the Company currently does not intend to raise additional capital this year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- OCUL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ocular Therapeutix Approves New CEO Compensation Package
- Ocular Therapeutix reports inducement grant under Nasdaq listing rule
- Ocular Therapeutix shares SOLR-R enrollment progress, next steps AXPAXLI
- EyePoint initiated with a Buy at Citi